MAP4

• Description:

  MAP4 is a selective group III mGluR antagonist in some electrophysiological systems[1].

• UNSPSC:

  12352211

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  MGluR

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/map4.html

• Solubility:

  10 mM in DMSO

• Smiles:

  OC([C@@](C)(N)CCP(O)(O)=O)=O

• Molecular Formula:

  C5H12NO5P

• Molecular Weight:

  197.13

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations:

  [1]Salt TE, Eaton SA. Distinct presynaptic metabotropic receptors for L-AP4 and CCG1 on GABAergic terminals: pharmacological evidence using novel alpha-methyl derivative mGluR antagonists, MAP4 and MCCG, in the rat thalamus in vivo. Neuroscience. 1995 Mar;65 (1) :5-13.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [157381-42-5]